{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T22:13:27Z","timestamp":1788300807282,"version":"build-2803163510"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","award":["402417\/2023-2"],"award-info":[{"award-number":["402417\/2023-2"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"Minas Gerais State Foundation of Support to the Research","doi-asserted-by":"publisher","award":["APQ-02585-25"],"award-info":[{"award-number":["APQ-02585-25"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"Minas Gerais State Foundation of Support to the Research","doi-asserted-by":"publisher","award":["RED-0067-23"],"award-info":[{"award-number":["RED-0067-23"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"Minas Gerais State Foundation of Support to the Research","doi-asserted-by":"publisher","award":["APQ-02167-21"],"award-info":[{"award-number":["APQ-02167-21"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.vaccine.2026.128990","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:55:08Z","timestamp":1785772508000},"page":"128990","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Recombinant vaccine plus anti-parasitic agent in an immunotherapeutic schedules induce partial regression of tegumentary leishmaniasis in a murine model"],"prefix":"10.1016","volume":"89","author":[{"given":"Camila S.","family":"Freitas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela P.","family":"Lage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breno L.","family":"Pimenta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina O.M.","family":"Falc\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel J.L.","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabela A.G.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel S.B.","family":"C\u00e2mara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie L.P.","family":"Sim\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana L.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o A.","family":"Oliveira-da-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00f3ris M.","family":"Abr\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexsandro S.","family":"Galdino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Ch\u00e1vez-Fumagalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno M.","family":"Roatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron","family":"Christodoulides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo A.F.","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.vaccine.2026.128990_bb0005","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.3389\/fmicb.2018.01308","article-title":"The binomial parasite-host immunity in the healing process and in reactivation of human tegumentary leishmaniasis","volume":"19","author":"Concei\u00e7\u00e3o-Silva","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2026.128990_bb0010","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1128\/CMR.6.3.230","article-title":"Leishmaniases of the New World: current concepts and implications for future research","volume":"6","author":"Grimaldi","year":"1993","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128990_bb0015","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00281-020-00788-y","article-title":"Leishmaniasis immunopathology-impact on design and use of vaccines, diagnostics and drugs","volume":"42","author":"Kaye","year":"2020","journal-title":"Semin Immunopathol"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128990_bb0020","doi-asserted-by":"crossref","first-page":"536","DOI":"10.4269\/ajtmh.1991.44.536","article-title":"Leishmaniasis in Bahia, Brazil: evidence that Leishmania amazonensis produces a wide spectrum of clinical disease","volume":"44","author":"Barral","year":"1991","journal-title":"Am J Trop Med Hyg"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128990_bb0025","doi-asserted-by":"crossref","first-page":"40804","DOI":"10.1038\/srep40804","article-title":"Comparative genomics of canine-isolated Leishmania (Leishmania) amazonensis from an endemic focus of visceral leishmaniasis in Governador Valadares, southeastern Brazil","volume":"16","author":"Valdivia","year":"2017","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128990_bb0030","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1590\/abd1806-4841.20142389","article-title":"Complementary exams in the diagnosis of American tegumentary leishmaniasis","volume":"89","author":"Gomes","year":"2014","journal-title":"An Bras Dermatol"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128990_bb0035","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1586\/eri.10.19","article-title":"Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis","volume":"8","author":"Goto","year":"2010","journal-title":"Expert Rev Anti-Infect Ther"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128990_bb0040","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1007\/s00436-022-07628-y","article-title":"A new immunochemotherapy schedule for visceral leishmaniasis in a hamster model","volume":"121","author":"Santana","year":"2022","journal-title":"Parasitol Res"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128990_bb0045","first-page":"272","article-title":"Immunotherapy and immunochemotherapy in visceral leishmaniasis: promising treatments for this neglected disease","volume":"13","author":"Roatt","year":"2014","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128990_bb0050","article-title":"Immunotherapy and immunochemotherapy in combating visceral leishmaniasis","volume":"17","author":"Yadagiri","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.vaccine.2026.128990_bb0055","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.imlet.2021.03.011","article-title":"Immunotherapy in treatment of leishmaniasis","volume":"233","author":"Akbari","year":"2021","journal-title":"Immunol Lett"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128990_bb0060","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3389\/fimmu.2020.00345","article-title":"Protective cellular immune response induction for cutaneous leishmaniasis by a new immunochemotherapy schedule","volume":"3","author":"Silva","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128990_bb0065","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cellimm.2017.11.001","article-title":"Recombinant prohibitin protein of Leishmania infantum acts as a vaccine candidate and diagnostic marker against visceral leishmaniasis","volume":"323","author":"Dias","year":"2018","journal-title":"Cell Immunol"},{"issue":"237","key":"10.1016\/j.vaccine.2026.128990_bb0070","article-title":"Leishmania lipophosphoglycan components: a potent target for synthetic neoglycoproteins as a vaccine candidate for leishmaniasis","volume":"1","author":"Mohammed","year":"2020","journal-title":"Carbohydr Polym"},{"key":"10.1016\/j.vaccine.2026.128990_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.pep.2020.105750","article-title":"A scalable and reproducible manufacturing process for Phlebotomus papatasi salivary protein PpSP15, a vaccine candidate for leishmaniasis","volume":"177","author":"Liu","year":"2021","journal-title":"Protein Expr Purif"},{"key":"10.1016\/j.vaccine.2026.128990_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2020.155247","article-title":"Th1 concomitant immune response mediated by IFN-gamma protects against sand fly delivered Leishmania infection: implications for vaccine design","volume":"147","author":"Seyed","year":"2021","journal-title":"Cytokine"},{"issue":"20","key":"10.1016\/j.vaccine.2026.128990_bb0085","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1016\/j.vaccine.2021.04.004","article-title":"A chimeric vaccine combined with adjuvant system induces immunogenicity and protection against visceral leishmaniasis in BALB\/c mice","volume":"39","author":"Ostolin","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128990_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.actatropica.2025.107796","article-title":"Advances in recombinant protein vaccines against Leishmania infantum: a systematic review of vaccinal constructs and delivery strategies","volume":"270","author":"Martins","year":"2025","journal-title":"Acta Trop"},{"key":"10.1016\/j.vaccine.2026.128990_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2019.103704","article-title":"Genome based screening of epitope ensemble vaccine candidates against dreadful visceral leishmaniasis using immunoinformatics approach","volume":"136","author":"Singh","year":"2019","journal-title":"Microb Pathog"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128990_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgeb.2024.100355","article-title":"Multi-epitope vaccine design against leishmaniasis using IFN-gamma inducing epitopes from immunodominant gp46 and gp63 proteins","volume":"22","author":"Dehghani","year":"2024","journal-title":"J Genet Eng Biotechnol"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128990_bb0105","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.3390\/vaccines10071146","article-title":"A recombinant chimeric protein-based vaccine containing T-cell epitopes from amastigote proteins and combined with distinct adjuvants, induces immunogenicity and protection against Leishmania infantum infection","volume":"10","author":"Lage","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128990_bb0110","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3390\/biology12060851","article-title":"Efficacy of an immunotherapy combining immunogenic chimeric protein plus adjuvant and amphotericin B against murine visceral leishmaniasis","volume":"12","author":"Vale","year":"2023","journal-title":"Biol-Basel"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128990_bb0115","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1080\/08982104.2017.1376682","article-title":"Liposomal formulations in the pharmacological treatment of leishmaniasis: a review","volume":"27","author":"Ortega","year":"2017","journal-title":"J Liposome Res"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128990_bb0120","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1590\/0037-8682-0138-2015","article-title":"New delivery systems for amphotericin B applied to the improvement of leishmaniasis treatment","volume":"48","author":"Ch\u00e1vez-Fumagalli","year":"2015","journal-title":"Rev Soc Bras Med Trop"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128990_bb0125","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1080\/15563650.2022.2043338","article-title":"Ivermectin: a mini-review","volume":"60","author":"Johnson-Arbor","year":"2022","journal-title":"Clin Toxicol (Phila)"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128990_bb0130","article-title":"Ivermectin: a multifaceted drug with a potential beyond anti-parasitic therapy","volume":"16","author":"Kaur","year":"2024","journal-title":"Cureus"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128990_bb0135","article-title":"Ivermectin treatment in humans for reducing malaria transmission","volume":"6","author":"Souza","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128990_bb0140","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s11250-022-03228-1","article-title":"In vitro anti-trypanosomal effect of ivermectin on Trypanosoma evansi by targeting multiple metabolic pathways","volume":"54","author":"Gupta","year":"2022","journal-title":"Trop Anim Health Prod"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128990_bb0145","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s00436-024-08178-1","article-title":"Considering ivermectin for treatment of schistosomiasis","volume":"123","author":"Golenser","year":"2024","journal-title":"Parasitol Res"},{"issue":"Suppl. 3","key":"10.1016\/j.vaccine.2026.128990_bb0150","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1093\/cid\/ciab238","article-title":"Scaling-Down mass ivermectin treatment for onchocerciasis elimination: modeling the impact of the geographical unit for decision making","volume":"72","author":"Stolk","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128990_bb0155","doi-asserted-by":"crossref","first-page":"951","DOI":"10.4269\/ajtmh.23-0645","article-title":"High efficacy of Ivermectin for Strongyloidiasis treatment","volume":"110","author":"Sengthong","year":"2024","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128990_bb0160","doi-asserted-by":"crossref","first-page":"51","DOI":"10.7883\/yoken1952.42.51","article-title":"Ivermectin, levamisole and thymic extract for chemotherapy and immunostimulation of visceral leishmaniasis in hamsters and mice","volume":"42","author":"Rifaat","year":"1989","journal-title":"Jpn J Med Sci Biol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128990_bb0165","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/vbz.2009.0030","article-title":"Effects of ivermectin on blood-feeding Phlebotomus papatasi, and the promastigote stage of Leishmania major","volume":"11","author":"Hanafi","year":"2011","journal-title":"Vector Borne Zoonotic Dis"},{"key":"10.1016\/j.vaccine.2026.128990_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2023.156143","article-title":"Exploring drug repositioning for leishmaniasis treatment: ivermectin plus polymeric micelles induce immunological response and protection against tegumentary leishmaniasis","volume":"164","author":"Freitas","year":"2023","journal-title":"Cytokine"},{"key":"10.1016\/j.vaccine.2026.128990_bb0175","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1128\/IAI.71.7.3988-3994.2003","article-title":"Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection","volume":"71","author":"Coelho","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2026.128990_bb0180","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.824968","article-title":"Characterization of differentially abundant proteins among Leishmania (Viannia) braziliensis strains isolated from atypical or typical lesions","volume":"12","author":"Esteves","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128990_bb0185","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1017\/S003118201600216X","article-title":"Leishmaniasis and various immunotherapeutic approaches","volume":"145","author":"Taslimi","year":"2018","journal-title":"Parasitology"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128990_bb0190","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1017\/S0031182021001906","article-title":"Immunochemotherapy for visceral leishmaniasis: combinatorial action of Miltefosine plus LBSapMPL vaccine improves adaptative Th1 immune response with control of splenic parasitism in experimental hamster model","volume":"149","author":"Carvalho","year":"2022","journal-title":"Parasitology"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128990_bb0195","doi-asserted-by":"crossref","DOI":"10.1111\/pim.13028","article-title":"LaSap vaccine: immunotherapy and immunochemotherapy associated with allopurinol in dogs naturally infected with Leishmania infantum","volume":"46","author":"Clasta","year":"2024","journal-title":"Parasite Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128990_bb0200","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1046\/j.1365-4362.2002.01336.x","article-title":"Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania (Leishmania) amazonensis vaccine plus antimonial","volume":"41","author":"Machado-Pinto","year":"2002","journal-title":"Int J Dermatol"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128990_bb0205","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3390\/pathogens12020314","article-title":"Immunotherapy using immunogenic mimotopes selected by phage display plus amphotericin B inducing a therapeutic response in mice infected with Leishmania amazonensis","volume":"12","author":"Soyer","year":"2023","journal-title":"Pathogens"},{"key":"10.1016\/j.vaccine.2026.128990_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.exppara.2020.108059","article-title":"Ivermectin presents effective and selective antileishmanial activity in vitro and in vivo against Leishmania infantum and is therapeutic against visceral leishmaniasis","volume":"221","author":"Reis","year":"2021","journal-title":"Exp Parasitol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128990_bb0215","doi-asserted-by":"crossref","first-page":"20275","DOI":"10.1038\/s41598-019-56336-8","article-title":"Immunotherapy using anti-PD-1 and anti-PD-L1 in Leishmania amazonensis-infected BALB\/c mice reduce parasite load","volume":"9","author":"Fonseca-Martins","year":"2019","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128990_bb0220","doi-asserted-by":"crossref","first-page":"1492770","DOI":"10.3389\/fchem.2024.1492770","article-title":"Aspidosperma nitidum reduces parasite load and modulates cytokines in BALB\/c mice infected with Leishmania (Leishmania) amazonensis","volume":"31","author":"Br\u00edgido","year":"2024","journal-title":"Front Chem"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128990_bb0225","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40265-013-0069-4","article-title":"Amphotericin B formulations: a comparative review of efficacy and toxicity","volume":"73","author":"Hamill","year":"2013","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128990_bb0230","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1517\/14656566.2015.973850","article-title":"An update on pharmacotherapy for leishmaniasis","volume":"16","author":"Sundar","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.vaccine.2026.128990_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110097","article-title":"Lipophosphoglycan-3 recombinant protein vaccine controls hepatic parasitism and prevents tissue damage in mice infected by Leishmania infantum chagasi","volume":"126","author":"Bastos","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.vaccine.2026.128990_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104272","article-title":"IFN-gamma(+) CD4(+)T-cell-driven prophylactic potential of recombinant LDBPK_252400 hypothetical protein of Leishmania donovani against visceral leishmaniasis","volume":"361","author":"Yadav","year":"2021","journal-title":"Cell Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128990_bb0245","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.parint.2014.04.002","article-title":"A comparative evaluation of efficacy of chemotherapy, immunotherapy and immunochemotherapy in visceral leishmaniasis-an experimental study","volume":"63","author":"Joshi","year":"2014","journal-title":"Parasitol Int"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128990_bb0250","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3389\/fimmu.2020.00345","article-title":"Protective cellular immune response induction for cutaneous Leishmaniasis by a new immunochemotherapy schedule","volume":"3","author":"Silva","year":"2020","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128990_bb0255","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/tmi.13210","article-title":"American tegumentary leishmaniasis in Brazil: a critical review of the current therapeutic approach with systemic meglumine antimoniate and short-term possibilities for an alternative treatment","volume":"24","author":"Carvalho","year":"2019","journal-title":"Trop Med Int Health"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128990_bb0260","article-title":"Interventions for American cutaneous and mucocutaneous leishmaniasis","volume":"8","author":"Pinart","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.vaccine.2026.128990_bb0265","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/2496713","article-title":"Review on the role of host immune response in protection and immunopathogenesis during cutaneous leishmaniasis infection","author":"Dubie","year":"2020","journal-title":"J Immunol Res"},{"key":"10.1016\/j.vaccine.2026.128990_bb0270","doi-asserted-by":"crossref","first-page":"2496713","DOI":"10.1155\/2020\/2496713","article-title":"Review on the Role of Host Immune Response in Protection and Immunopathogenesis during Cutaneous Leishmaniasis Infection","volume":"2020","author":"Dubie","year":"2020","journal-title":"J Immunol Res."},{"key":"10.1016\/j.vaccine.2026.128990_bb0275","doi-asserted-by":"crossref","DOI":"10.1155\/jotm\/5579789","article-title":"The impact of Ivermectin on immune response and wound healing in a mouse model infected with Leishmania major","volume":"2025","author":"Rahmani","year":"2025","journal-title":"J Trop Med"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128990_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2021.152057","article-title":"Immune induction by adjuvanted Leishmania donovani vaccines against the visceral leishmaniasis in BALB\/c mice","volume":"226","author":"Goyal","year":"2021","journal-title":"Immunobiology"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128990_bb0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001687","article-title":"Immunodominant antigens of Leishmania chagasi associated with protection against human visceral leishmaniasis","volume":"6","author":"Ab\u00e1nades","year":"2012","journal-title":"PLoS Negl Trop Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26007991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26007991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T21:21:23Z","timestamp":1788297683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26007991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":57,"alternative-id":["S0264410X26007991"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128990","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recombinant vaccine plus anti-parasitic agent in an immunotherapeutic schedules induce partial regression of tegumentary leishmaniasis in a murine model","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128990","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"128990"}}